Prothena Co. plc (NASDAQ:PRTA – Get Rating) insider Hideki Garren sold 8,000 shares of the business’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $30.00, for a total transaction of $240,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ PRTA traded up $0.77 on Friday, hitting $31.49. The stock had a trading volume of 202,213 shares, compared to its average volume of 434,659. Prothena Co. plc has a 52-week low of $21.06 and a 52-week high of $79.75. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 25.81 and a beta of 1.30. The firm has a 50-day moving average of $26.98 and a 200-day moving average of $33.38.
Prothena (NASDAQ:PRTA – Get Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.07. Prothena had a net margin of 33.45% and a return on equity of 16.02%. The business had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.23 million. Equities research analysts expect that Prothena Co. plc will post -2.53 EPS for the current year.
A number of brokerages recently commented on PRTA. JMP Securities dropped their price target on shares of Prothena from $77.00 to $50.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 25th. StockNews.com began coverage on shares of Prothena in a research note on Thursday, March 31st. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.00.
Hedge funds and other institutional investors have recently bought and sold shares of the business. UBS Group AG increased its holdings in shares of Prothena by 4,564.1% in the 3rd quarter. UBS Group AG now owns 77,517 shares of the biotechnology company’s stock worth $5,522,000 after buying an additional 75,855 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of Prothena by 204.9% in the 3rd quarter. Captrust Financial Advisors now owns 2,003 shares of the biotechnology company’s stock worth $143,000 after buying an additional 1,346 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Prothena in the 3rd quarter worth $269,000. Moors & Cabot Inc. bought a new position in shares of Prothena in the 3rd quarter worth $1,653,000. Finally, Spire Wealth Management increased its holdings in shares of Prothena by 938.8% in the 4th quarter. Spire Wealth Management now owns 1,070 shares of the biotechnology company’s stock worth $53,000 after buying an additional 967 shares during the last quarter. Institutional investors and hedge funds own 92.64% of the company’s stock.
Prothena Company Profile (Get Rating)
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.